No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - CelLBxHealth said on Friday that it had entered into a master services agreement with AstraZeneca, establishing the company as a qualified service provider to the global pharmaceutical group.
The AIM-traded company, formerly known as Angle and which specialises in circulating tumour cell, or CTC, solutions for research, drug development and clinical oncology, said the agreement would allow it to support AstraZeneca's drug discovery and development work through CTC-powered analytics of clinical trial samples.
It said the work would use its Parsortix platform, which is designed to analyse circulating tumour cells.
Chief executive officer Peter Collins said the agreement would give AstraZeneca access to CelLBxHealth's capabilities across its development pipeline.
"We are delighted to enter into this master services agreement which enables AstraZeneca to access our capabilities across their development pipeline," Collins said.
"We look forward to delivering strong and productive outcomes through this framework."
At 1354 BST, shares in CelLBxHealth were up 28.58% at 2.22p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.